Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

At 25-month follow-up, durvalumab (D) + tremelimumab + platinum–etoposide (PE) did not improve overall survival (n=805; 10.4 vs 10.5 months; HR 0.82; 95% CI 0.68–1.00; p=0.045); but D+PE showed sustained overall survival vs PE (12.9 vs 10.5 months; 0.75; 0.62–0.91; p=0.0032).

The Lancet Oncology